CJC-1295
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) consisting of 30 amino acids with strategic modifications designed to enhance stability and prolong biological activity. Originally developed as a long-acting alternative to native GHRH, CJC-1295 incorporates amino acid substitutions that confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation, extending its half-life from minutes to days.
This peptide has gained significant attention in anti-aging and regenerative medicine due to its ability to stimulate sustained endogenous growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion. CJC-1295's unique pharmacokinetic profile enables less frequent dosing while maintaining therapeutic efficacy, distinguishing it from other growth hormone secretagogues and contributing to its clinical utility in hormone optimization protocols.
Overview
CJC-1295 demonstrates superior stability compared to native GHRH through strategic amino acid modifications that eliminate DPP-4 cleavage sites while preserving GHRH receptor binding affinity. The peptide exists in two forms: CJC-1295 with Drug Affinity Complex (DAC) providing extended half-life, and CJC-1295 without DAC offering more physiological pulsatile release patterns. The compound is metabolized primarily through peptidase enzymes and eliminated via renal excretion.
Chemical structure & Properties
- Molecular Formula: C165H271N47O46
- Molecular Weight: 3,647.28 Da
- Sequence: Modified GRF(1-29) with Lys substitution and maleimido-propionyl-Lys attachment
- Half-life: 6-8 days (with DAC), 30 minutes (without DAC)
- Stability: Enhanced resistance to DPP-4 degradation through amino acid modifications
Mechanism of Action
CJC-1295 exerts its therapeutic effects through multiple interconnected molecular pathways:
Clinical Applications and
Research Evidence
Current Clinical Evidence
Safety Profile and Considerations
Regulatory Status and
Legal Considerations
FDA Status
- Classification: Investigational peptide - not approved for therapeutic use
- Approval Status: No FDA approval for human clinical applications
- Research Use: Limited to approved clinical trials and research protocols
- Regulatory Position: Subject to evolving peptide compound regulations (2023 changes)
WADA Status
- Classification: Prohibited under S2: Peptide Hormones, Growth Factors
- Athletic Use: Banned in competitive sports and athletic competitions
- Testing: Detectable through specialized anti-doping analysis methods
- Enforcement: Subject to sporting sanctions and competition disqualification
Legal Availability
- Commercial Status: Not legally available as prescription medication
- Market Presence: Available through research chemical suppliers and compounding pharmacies
- Quality Control: Limited regulatory oversight for purity, potency, and authenticity
- Clinical Use: Restricted to research institutions and experimental protocols
Administration and Dosing
Considerations
The Paragon Method: Step-by-Step
Clinical Considerations
Important Guidelines:
- No FDA-approved dosing recommendations exist for human use
- Individual response varies based on age, health status, and baseline hormone levels
- Regular monitoring of IGF-1 levels recommended to prevent excessive elevation
- Medical supervision strongly advised for any therapeutic application
- Quality and purity of research chemicals cannot be guaranteed
Priority Research Areas
Clinical Development Priorities:
- Large-scale, placebo-controlled trials for various therapeutic indications
- Long-term safety studies including comprehensive carcinogenicity assessment
- Optimal dosing protocols and treatment duration guidelines
- Combination therapy studies with other peptides and hormones
- Age-specific efficacy and safety evaluations
Emerging Applications
Investigational Uses:
- Age-related sarcopenia and frailty prevention
- Post-surgical recovery and wound healing enhancement
- Metabolic syndrome and insulin resistance management
- Cognitive function preservation and neuroprotection
- Osteoporosis prevention and bone health optimization
- Sleep disorders and circadian rhythm normalization
Combination Therapies
Synergistic Research:
- CJC-1295 plus Ipamorelin for enhanced GH release
- Integration with testosterone replacement therapy
- Combination with other regenerative peptides (BPC-157, TB-500)
- Synergistic effects with lifestyle interventions and exercise protocols
Conclusion
CJC-1295 represents a promising long-acting growth hormone-releasing hormone analog with demonstrated efficacy in stimulating endogenous GH and IGF-1 secretion. Its unique pharmacokinetic profile and favorable safety data distinguish it as a potential therapeutic tool for growth hormone optimization, body composition enhancement, and anti-aging applications.
However, the current clinical evidence base remains limited, with most data derived from small-scale, short-term studies. The lack of FDA approval, regulatory restrictions, and limited long-term safety data necessitate careful consideration and medical supervision for any therapeutic application.
Patients considering CJC-1295 therapy should engage in thorough discussions with qualified healthcare providers to weigh potential benefits against risks and explore evidence-based treatment alternatives. Future research will be critical in determining CJC-1295's role in clinical medicine, particularly in healthy aging, metabolic disorders, and hormone optimization protocols. Until comprehensive clinical trials are completed, its use should remain limited to research settings under appropriate medical oversight.
CJC-1295 SCIENTIFIC
DATA SUMMARY
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. CJC-1295 is not approved by the FDA for human therapeutic use. Patients should consult with qualified healthcare providers before considering any peptide therapy.
The content reflects current scientific literature and regulatory status as of 2025.